Kaigene Inc. has entered into an exclusive global licensing agreement with Celltrion Inc. for two of Kaigene's nonclinical-stage assets, KG006 and KG002.

Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune ...

November is National Diabetes Awareness Month, a time to talk about the disease that affects more than 38 million people ...

U.S. President Donald Trump's embrace of an old generic drug called leucovorin for use against a rare disorder that causes ...

Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...

SAN FRANCISCO -- Two studies demonstrated the benefits of treating juvenile myasthenia gravis (MG) with newer drugs.

Determining the type of diabetes a patient has at diagnosis can be challenging, and health care professionals should focus on each patient’s clinical condition when determining initial treatment, ...

The US Food and Drug Administration (FDA) has granted breakthrough device designation to Augurex Life Sciences’ SPINEstat ...

Asahi Kasei, a global provider of healthcare and pharmaceutical solutions, announced that Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules), has been included ...

Adolescents and young adults with preexisting autoimmune disease are more likely to develop type 1 diabetes than those ...

Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data will be presented at the 2025 American Society of Nephrology Kidney Week, taking place from November 6 to 9 ...